Abstract: The present invention relates to a solid or liquisolid formulation comprising corallopyronin A, wherein the formulation comprises an amorphous solid dispersion of corallopyronin A embedded in a water-soluble polymer or corallopyronin A loaded onto porous silica.

Abstract: The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.

Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.